Neuraxis, Inc. (NRXS)

Neuraxis, Inc. (NRXS) has announced an important update regarding its equity compensation plan. The company executed a previously approved Stock Option Exchange, converting 1,319,394 outstanding stock options into an equivalent number of restricted stock units (RSUs). Additionally, the Compensation Committee approved new RSU grants for executives and one-time equity awards for independent directors to address historical under-compensation.

NeurAxis, Inc. (NRXS) reported a significant 115.7% revenue surge in Q2 2026, reaching $1.9 million, and an expanded gross margin of 85.9%. Despite this, the stock dipped by 8.6% following the earnings release, as the company experienced a wider net loss and increased operating expenses due to investments in commercialization and clinical development. Management anticipates continued support for gross margins from favorable reimbursement mixes but expects higher cash burn in the second half of 2026 as it adds personnel and increases R&D spending.

NeurAxis (NRXS) shares fell 8.6% despite reporting a strong 115.7% Q2 revenue increase to $1.9 million, its highest quarterly performance yet. The company saw an expanded gross margin of 85.9% due to increased average selling prices for its IB-Stim unit, driven by a shift towards full-reimbursement insurance patients. Despite the revenue surge and narrowed loss per share, the net and operating losses widened as the company invested heavily in commercialization and R&D.

NeurAxis (NRXS) reported strong Q2 2026 financial results, with revenue up 116% year-over-year to $1.928 million, driven by increased payer and reimbursement coverage and the Category 1 CPT code for PENFS. The company is strategically focusing on maximizing execution in covered markets and expanding into the Veterans Administration healthcare system, while also actively pursuing additional insurance coverage with key payers to achieve its target of over 200 million covered lives by the end of 2027. Despite increased operating expenses due to investments in sales, marketing, and R&D for new indications, NeurAxis aims for cash flow breakeven in the future, confident that expanded coverage and aggressive market penetration will drive significant revenue growth.

NeurAxis, Inc. announced record second-quarter 2026 financial results, with revenues increasing 116% year over year to $1.9 million, primarily due to the Category I CPT code assignment for Percutaneous Electric Nerve Field Stimulation (PENFS). The company expanded its gross margin and reduced cash used in operations while securing FDA clearance for new indications and a Veterans Affairs contract. NeurAxis is focusing on expanding commercial insurance coverage to drive sustainable long-term growth for its IB-Stim technology.